INTELLIGENT BIO SOLUTIONS INC. Operating Lease, Right-of-Use Asset, Amortization Expense
INTELLIGENT BIO SOLUTIONS INC. (INBS) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $381.29 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-19.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-19
- INTELLIGENT BIO SOLUTIONS INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $225.31K, a 238.67% increase year-over-year.
- INTELLIGENT BIO SOLUTIONS INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-06-30 was $66.53K, a 11.18% increase year-over-year.
- INTELLIGENT BIO SOLUTIONS INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-09-30 was $61.49K, a 2.55% increase year-over-year.
- INTELLIGENT BIO SOLUTIONS INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-06-30 was $59.84K, a 3.03% increase year-over-year.
- INTELLIGENT BIO SOLUTIONS INC. operating lease, right-of-use asset, amortization expense for fiscal 2026 was $381.29K, a 53.81% increase from fiscal 2025.
- INTELLIGENT BIO SOLUTIONS INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $247.90K, a 3.84% increase from fiscal 2024.
- INTELLIGENT BIO SOLUTIONS INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $238.73K, a 56.80% increase from fiscal 2023.
- INTELLIGENT BIO SOLUTIONS INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $152.25K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $225.31K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-19 | $381.29K 10-K · filed 2026-08-19 | |||
| 2026-03-31 | $155.97K 10-Q · filed 2026-05-13 | ||||
| 2025-06-30 | $66.53K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-19 | $247.90K 10-K · filed 2026-08-19 | $243.63K 10-K · filed 2025-08-15 | ||
| 2025-03-31 | $181.37K 10-Q · filed 2026-05-13 | ||||
| 2024-09-30 | $61.49K 10-Q · filed 2024-11-07 | $121.33K derived: sum of 2 quarters · filed 2025-08-15 | $181.39K derived: sum of 3 quarters · filed 2025-08-15 | $240.26K derived: sum of 4 quarters · filed 2025-08-15 | |
| 2024-06-30 | $59.84K derived: 10-K 12 month − 10-Q 9 month · filed 2025-08-15 | $119.90K derived: sum of 2 quarters · filed 2025-08-15 | $178.77K derived: sum of 3 quarters · filed 2025-08-15 | $238.73K 10-K · filed 2025-08-15 | |
| 2024-03-31 | $60.06K 10-Q · filed 2024-05-08 | $118.93K derived: sum of 2 quarters · filed 2024-05-08 | $178.89K 10-Q · filed 2024-05-08 | $236.97K derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-12-31 | $58.87K 10-Q · filed 2024-02-09 | $118.83K 10-Q · filed 2024-02-09 | $176.91K derived: sum of 3 quarters · filed 2024-11-07 | $222.46K derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-09-30 | $59.96K 10-Q · filed 2024-11-07 | $118.04K derived: sum of 2 quarters · filed 2024-11-07 | $163.59K derived: sum of 3 quarters · filed 2024-11-07 | $212.21K derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $58.08K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-18 | $103.63K derived: sum of 2 quarters · filed 2024-09-18 | $152.25K derived: sum of 3 quarters · filed 2024-09-18 | $152.25K 10-K · filed 2024-09-18 | |
| 2023-03-31 | $45.55K 10-Q · filed 2024-05-08 | $94.17K derived: sum of 2 quarters · filed 2024-05-08 | $94.17K 10-Q · filed 2024-05-08 | ||
| 2022-12-31 | $48.62K 10-Q · filed 2024-02-09 | $48.62K 10-Q · filed 2024-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| enVVeno Medical Corp (NVNO) | United States | $0.006B | -0.48 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Co-Diagnostics, Inc. (CODX) | United States | $0.007B | -0.32 |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |